Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NYSE - Delayed Quote USD

Eli Lilly and Company (LLY)

Compare
839.96
+105.06
+(14.30%)
At close: April 17 at 4:00:02 PM EDT
844.40
+4.44
+(0.53%)
After hours: April 17 at 7:59:57 PM EDT
Loading Chart for LLY
  • Previous Close 734.90
  • Open 840.80
  • Bid 843.00 x 800
  • Ask 844.99 x 1000
  • Day's Range 821.84 - 858.00
  • 52 Week Range 677.09 - 972.53
  • Volume 10,091,602
  • Avg. Volume 3,725,945
  • Market Cap (intraday) 754.275B
  • Beta (5Y Monthly) 0.50
  • PE Ratio (TTM) 71.91
  • EPS (TTM) 11.68
  • Earnings Date May 1, 2025
  • Forward Dividend & Yield 6.00 (0.71%)
  • Ex-Dividend Date Feb 14, 2025
  • 1y Target Est 1,006.09

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

www.lilly.com

47,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LLY

View More

Performance Overview: LLY

Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LLY
8.99%
S&P 500 (^GSPC)
10.18%

1-Year Return

LLY
12.61%
S&P 500 (^GSPC)
5.19%

3-Year Return

LLY
186.01%
S&P 500 (^GSPC)
20.26%

5-Year Return

LLY
467.80%
S&P 500 (^GSPC)
83.77%

Compare To: LLY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LLY

View More

Valuation Measures

As of 4/17/2025
  • Market Cap

    754.27B

  • Enterprise Value

    784.50B

  • Trailing P/E

    71.73

  • Forward P/E

    36.76

  • PEG Ratio (5yr expected)

    1.22

  • Price/Sales (ttm)

    16.86

  • Price/Book (mrq)

    53.15

  • Enterprise Value/Revenue

    17.42

  • Enterprise Value/EBITDA

    51.52

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    23.51%

  • Return on Assets (ttm)

    15.33%

  • Return on Equity (ttm)

    84.26%

  • Revenue (ttm)

    45.04B

  • Net Income Avi to Common (ttm)

    10.59B

  • Diluted EPS (ttm)

    11.68

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.43B

  • Total Debt/Equity (mrq)

    244.62%

  • Levered Free Cash Flow (ttm)

    1.32B

Research Analysis: LLY

View More

People Also Watch